Alzheimer's Clinical Trials in Denver
View 27 new treatments for Alzheimer's in Denver, CO, and other areas near me, such as Arvada, Aurora, Centennial, Lakewood, Thornton and Westminster. Every day, Power helps hundreds of alzheimers patients connect with leading medical research.Semaglutide for Early Alzheimer's Disease
Novo Nordisk Clinic, Denver + 3 more
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.Show More
Remternetug for Alzheimer's Disease
Eli Lilly Clinic, Boulder + 3 more
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.Show More
Donanemab for Early Alzheimer's Disease
Eli Lilly Clinic, Boulder + 3 more
This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.Show More
AR1001 for Alzheimer's Disease
AriBio Clinic, Englewood + 3 more
This trial tests AR1001, a medicine for early Alzheimer's Disease. It focuses on people in the early stages of Alzheimer's, aiming to improve their condition through multiple mechanisms.Show More
Remternetug for Alzheimer's Disease
Eli Lilly Clinic, Boulder + 1 more
This trial tests remternetug, a drug given by injection or IV, in people with early Alzheimer's disease. It aims to find out if the drug is safe and can help improve symptoms or slow down the disease.Show More
Long-Term Safety of Simufilam for Alzheimer's Disease
Cassava Sciences Clinic, Denver + 1 more
The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.Show More
No Placebo Trial
Donanemab for Alzheimer's Disease
Eli Lilly Clinic, Aurora + 4 more
This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.Show More
AVP-786 for Agitation in Alzheimer's Disease
Avanir Clinic, Denver + 1 more
This trial is testing a medication called AVP-786 on individuals who have taken part in previous studies. The goal is to see if this medication can help with their conditions over time.Show More
No Placebo Trial
Semaglutide for Early Alzheimer's Disease
Novo Nordisk Clinic, Denver + 3 more
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.Show More
Piromelatine for Alzheimer's Disease
Neurim Clinic, Denver + 1 more
This trial tests piromelatine, a pill taken before bed, in people with mild Alzheimer's who lack a specific genetic variation. The goal is to see if it can improve brain function and slow down dementia progression.Show More
Frequently Asked Questions
How much do alzheimer's clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.
Do I need to be insured to participate in a medical study?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
How do alzheimer's clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across alzheimers trials in Denver, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for alzheimers patients is 6 Months.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.
Where in Denver is research being conducted for alzheimer's?
Prominent neighborhoods in Denver conducting Alzheimer's clinical trials include areas around the Mile High Research Center and Denver Neurological Research, primarily in the central and southern parts of the city. Approximately 18 trials are ongoing as of 2024.
What promising new drugs are being tested?
In Denver, Alzheimer's research is focusing on treatments like Monoclonal Antibodies and Glucagon-like peptide-1 receptor agonists. Notable drugs being studied include Donanemab, Semaglutide, and Lecanemab.